# Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

> **NCT01518413** · PHASE1 · COMPLETED · sponsor: **HMeany** · enrollment: 17 (actual)

## Conditions studied

- Rhabdomyosarcoma and Other Soft Tissue Sarcomas
- Ewing's Sarcoma Family of Tumors
- Osteosarcoma
- Neuroblastoma
- Brain Tumors

## Interventions

- **DRUG:** sorafenib
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT01518413
- **Lead sponsor:** HMeany
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518413, "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01518413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*